Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis

Single-agent poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved as the first targeted therapy available for patients with BRCA-mutated HER2-negative metastatic breast cancer. This meta-analysis aimed to better evaluate activity, efficacy and safety of single-agent PARPi in thi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:ESMO Open
Main Authors: Poggio, Francesca, Bruzzone, Marco, Ceppi, Marcello, Conte, Benedetta, Martel, Samuel, Maurer, Christian, Tagliamento, Marco, Viglietti, Giulia, Del Mastro, Lucia, de Azambuja, Evandro, Lambertini, Matteo
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2018
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012556/
https://ncbi.nlm.nih.gov/pubmed/29942664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000361
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares